EIF2AK3 and neoplasm: Some antitumour drugs release CRT by increasing the production of ROS in tumour cells, phosphorylating PERK/PKR and eIF2α, activating PI3K/AKT pathway, and displacing CRT/Annexin A1 to the cell membrane C/EBPα mRNA binding, promote C/EBPα expression.